Importer of Controlled Substances; Notice of Registration, 10676 [05-4235]

Download as PDF 10676 Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices Drug Schedule 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). 4-Methoxyamphetamine (7411) ... Amphetamine (1100) .................... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Codeine (9050) ............................. Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Methadone Intermediate (9254) ... Morphine (9300) ........................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ I I I II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambrex North Brunswick, Inc., Technology Centre of New Jersey to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cambrex North Brunswick, Inc., Technology Centre of New Jersey to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. DEPARTMENT OF JUSTICE By Notice dated September 16, 2004, and published in the Federal Register on September 30, 2004, (69 FR 58539– 58540), Cambridge Isotope Laboratory, 50 Frontage Road, Andover, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated September 28, 2004 and published in the Federal Register on October 14, 2004, (69 FR 61043), Cambrex North Brunswick, Inc., Technology Center of New Jersey, 661 Highway One, North Brunswick, New Jersey 08902, made application by renewal to the Drug Enforcement Jkt 205001 BILLING CODE 4410–09–P Manufacturer of Controlled Substances; Notice of Registration BILLING CODE 4410–09–P 19:07 Mar 03, 2005 Dated: February 23, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4235 Filed 3–3–05; 8:45 am] Drug Enforcement Administration Dated: February 23, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4212 Filed 3–3–05; 8:45 am] VerDate jul<14>2003 Administration (DEA) to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in Schedule II. The company plans to import the listed controlled substances to manufacture amphetamine. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. sections 823(a) and 952(a) and determined that the registration of Cambrex North Brunswick, Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Cambrex North Brunswick, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. sections 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Drug Schedule Methaqualone (2565) ................... Dimethyltryptamine (7435) ........... Amphetamine (1100) .................... Methamphetamine (1105) ............ Pentobarbital (2270) ..................... Secobarbital (2315) ...................... PO 00000 Frm 00086 Fmt 4703 Sfmt 4703 I I II II II II Drug Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Oxycodone (9143) ........................ Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... Methadone (9250) ........................ Dextropropoxyphene (9273) ......... Morphine (9300) ........................... Fentanyl (9801) ............................ Schedule II II II II II II II II II II II II The company plans to manufacture small quantities of the listed controlled substances to produce isotope labeled standards for drug analysis. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambridge Isotope Laboratory to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cambridge Isotope Laboratory to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: February 22, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4204 Filed 3–3–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated September 28, 2004, and published in the Federal Register on October 14, 2004, (69 FR 61043), Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: E:\FR\FM\04MRN1.SGM 04MRN1

Agencies

[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Page 10676]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-4235]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated September 28, 2004 and published in the Federal 
Register on October 14, 2004, (69 FR 61043), Cambrex North Brunswick, 
Inc., Technology Center of New Jersey, 661 Highway One, North 
Brunswick, New Jersey 08902, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as an importer of 
Phenylacetone (8501), a basic class of controlled substance listed in 
Schedule II.
    The company plans to import the listed controlled substances to 
manufacture amphetamine.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. sections 823(a) and 952(a) and determined that 
the registration of Cambrex North Brunswick, Inc. to import the basic 
classes of controlled substances is consistent with the public interest 
and with United States obligations under international treaties, 
conventions, or protocols in effect on May 1, 1971, at this time. DEA 
has investigated Cambrex North Brunswick, Inc. to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. sections 952(a) and 958(a), 
and in accordance with 21 CFR 1301.34, the above named company is 
granted registration as an importer of the basic class of controlled 
substance listed.

    Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-4235 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.